共 50 条
- [3] Deferasirox for up to 3 years leads to continued improvement of myocardial T2☆ in patients with β-thalassemia major [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (06): : 842 - 848
- [5] Continued improvement in myocardial T2☆ over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (01): : 48 - 54
- [6] Role of cardiac magnetic resonance T1 mapping in comparison to T2* for cardiac iron overload assessment in transfusion-dependent thalassemia major patients [J]. EGYPTIAN JOURNAL OF RADIOLOGY AND NUCLEAR MEDICINE, 2023, 54 (01):
- [7] Role of cardiac magnetic resonance T1 mapping in comparison to T2* for cardiac iron overload assessment in transfusion-dependent thalassemia major patients [J]. Egyptian Journal of Radiology and Nuclear Medicine, 54
- [9] A T2*MRI PROSPECTIVE SURVEY ON HEART AND LIVER IRON IN THALASSEMIA MAJOR PATIENTS TREATED WITH DEFERASIROX, DEFERIPRONE AND DESFERRIOXAMINE [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 426 - 426